Zhang DF, et al. - The target of researchers was to analyze the effectiveness and safety of tacrolimus in the treatment of Henoch-Schonlein purpura nephritis (HSPN) in children. Additionally, they intended to assess the potential impact of CYP3A5 genotype. It was determined that tacrolimus could prove to be an effective and well-tolerated drug for the treatment of HSPN in children. Findings displayed that CYP3A5 polymorphism exerted a prominent impact on tacrolimus concentration.